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X-linked retinitis pigmentosa (XLRP) is a clinically and genetically heterogeneous degenerative disease of the retina.
At least five loci have been mapped for XLRP; of these, RP2 and RP3 account for 10%–20% and 70%–90% of
genetically identifiable disease, respectively. However, mutations in the respective genes, RP2 and RPGR, were
detected in only 10% and 20% of families with XLRP. Mutations in an alternatively spliced RPGR exon, ORF15,
have recently been shown to account for 60% of XLRP in a European cohort of 47 families. We have performed,
in a North American cohort of 234 families with RP, a comprehensive screen of the RP2 and RPGR (including
ORF15) genes and their 5′ upstream regions. Of these families, 91 (39%) show definitive X-linked inheritance, an
additional 88 (38%) reveal a pattern consistent with X-linked disease, and the remaining 55 (23%) are simplex
male patients with RP who had an early onset and/or severe disease. In agreement with the previous studies, we
show that mutations in the RP2 gene and in the original 19 RPGR exons are detected in !10% and ∼20% of
XLRP probands, respectively. Our studies have revealed RPGR-ORF15 mutations in an additional 30% of 91 well-
documented families with X-linked recessive inheritance and in 22% of the total 234 probands analyzed. We suggest
that mutations in an as-yet-uncharacterized RPGR exon(s), intronic changes, or another gene in the region might
be responsible for the disease in the remainder of this North American cohort. We also discuss the implications of
our studies for genetic diagnosis, genotype-phenotype correlations, and gene-based therapy.
Introduction
Retinitis pigmentosa (RP) is a clinically and genetically
heterogeneous group of retinal degenerative diseases,
characterized by night blindness, progressive restriction
of the visual field, and pigmentary retinopathy. At least
28 different genetic loci have been mapped for autosomal
dominant, autosomal recessive, and X-linked forms of RP
(see RetNet Web site). The X-linked RP subtype (XLRP
[MIM 268000]) is relatively severe, with an early age at
onset and rapid progression, accounting for 10%–20%
of families with RP (Bird 1975; Fishman 1978). XLRP is
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genetically heterogeneous, with five mapped loci: RP2
(MIM 312600) (Bhattacharya et al. 1984), RP3 (MIM
312610) (Musarella et al. 1988), RP6 (MIM312612)
(Breuer et al. 2001), RP23 (Hardcastle et al. 2000) and
RP24 (MIM 300155) (Gieser et al. 1998). On the basis
of linkage analysis, RP2 is predicted to account for
10%–20% and RP3 for 70%–90% of XLRP (Musarella
et al. 1990; Ott et al. 1990; Teague et al. 1994; Fujita et
al. 1997). The RP2 and RPGR (for RP3) genes for these
two major loci have now been cloned (Meindl et al. 1996;
Roepman et al. 1996; Schwahn et al. 1998).
The RP2 gene is composed of five exons, encoding a
ubiquitously expressed polypeptide of 350 amino acids
(Schwahn et al. 1998). The N-terminus of the protein is
homologous to cofactor C, which is involved in b-tubulin
folding (Tian et al. 1996). A majority of the mutations
in RP2 are localized in the cofactor C homologous do-
main and are predicted to generate a truncated protein
(Schwahn et al. 1998; Mears et al. 1999). Further se-
quence analysis and secondary structure predictions
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show that residues 207–244 of the RP2 protein are ho-
mologous to a pig microtubule-associated protein, the g-
subunit of T-complex, and residues 250–317 show ho-
mology to NM23, a member of the nucleoside di-
phosphate kinase family (Miano et al. 2001). In tran-
siently transfected cultured cells, the RP2 protein is lo-
calized to the plasma membrane, and mutations in the
first five amino acids disrupt this localization (Chapple
et al. 2000; Schwahn et al. 2001). These studies suggest
that RP2 is a membrane- and/or tubulin-associated chap-
erone or signaling protein.
RPGR, the RP3 gene, spans 70 kb and was originally
reported to include 19 exons encoding a protein of 815
amino acids. The N-terminal region of RPGR contains
tandem repeats similar to RCC1 (called RCC1-like do-
main or RLD), which is a guanine nucleotide exchange
factor (GEF) for Ran-GTPase (Ohtsubo et al. 1987; Dri-
vas et al. 1990). On the basis of RCC1 crystal structure
(Renault et al. 1998), the RPGR protein is predicted to
have a seven-blade b-propeller structure and to function
as a GEF for a small GTP-binding protein. Since the
original reports (Meindl et al. 1996; Roepman et al.
1996), several groups have identified new exons andmul-
tiple RPGR transcripts (at least 14) with extensive al-
ternative splicing (Yan et al. 1998; Kirschner et al. 1999;
Vervoort et al. 2000; Kirschner et al. 2001). One of these
new exons is ORF15, which is contiguous with exon 15
(located in the original intron 15). It spans 1.6 kb, is
highly repetitive, and encodes a putative glutamic acid–
and glycine-rich domain. ORF15 was also shown to be
a mutational hot spot, with presumed mutations in 28
of 47 patients with XLRP (Vervoort et al. 2000). Inherent
complexity generated by extensive alternative splicinghas
produced inconsistent results of RPGR intracellular lo-
calization and made the functional studies difficult. A
mouse model generated by an in-frame deletion of Rpgr
exons 4–6 showed a phenotype of slow cone and rod
degeneration (Hong et al. 2000). Two proteins, PDE-d
and RPGR-interacting protein (RPGRIP), have been
identified by the yeast two-hybrid method (Linari et al.
1999; Boylan and Wright 2000; Roepman et al. 2000b).
The RPGR and RPGRIP proteins have been localized to
the connecting cilia and rod outer segments (Hong et al.
2001; Roepman et al. 2000a).
Consistent with genetic studies, mutations in RP2 are
observed in 7%–18% of XLRP (Hardcastle et al. 1999;
Mears et al. 1999). However, the reported mutation
screens have shown a remarkably low frequency of dis-
ease-causing sequence changes (11%–26%) in RPGR
(Buraczynska et al. 1997; Sharon et al. 2000). RPGR-
ORF15 was recently reported to account for 60% of
missing mutations in a European XLRP cohort (Ver-
voort et al. 2000). Recently, RPGR-ORF15 mutations
have also been described in families with X-linked cone
degeneration (Mears et al. 2000; Demirci et al. 2002;
Yang et al. 2002). These previous investigations, how-
ever, undertook limited mutation screenings of relatively
small patient cohorts. To determine the spectrum of
mutations in a large XLRP cohort from North America,
we performed a comprehensive analysis of the RP2 and
RPGR genes, including all reported exons and their 5′
upstream regions. The results demonstrate putative dis-
ease-causing mutations in 56 (62%) of 91 well-docu-
mented North American families with XLRP and in 100
(43%) of the total of 234 probands analyzed.
Subjects, Material, and Methods
Patients and Families
We have performed mutation analysis in a cohort of
234 putative XLRP families of predominantly (195%)
white ancestry from North America. Although many
families are believed to have mixed ethnicity, we can be
certain only of five Hispanic and two African American
families in our cohort. Of the 234 families, 160 were
referred by collaborating clinicians, and 74 were ob-
tained by referral from the Foundation Fighting Blind-
ness as part of the Retinitis Pigmentosa Research Center
(RPRC). The diagnosis of XLRP in the clinician-referred
families was made by ocular examination, visual field
testing, and/or electroretinograms (ERGs), as well as by
pedigree analysis (Jacobson et al. 1989; Sieving 1995).
For individuals referred by the RPRC, the clinical in-
formation was less complete and the diagnosis was based
on ophthalmic examination and pedigree data. Families
with XLRP were subdivided into three categories that
reflected the strength of the clinical documentation and
the family history of disease (see table 5). Of the clini-
cian-referred patients, 39% had a family history with at
least two generations of affected males that were related
through an unaffected or carrier female (total of 91; class
A). An additional 38% were referred either by clinicians
or through the RPRC and reported a family history of
two or more affected male subjects, in a single or mul-
tiple generations (total of 88; class B). The remaining
probands were the only affected males in the family with
RP (simplex males), but, in most instances, were given
the tentative diagnosis of XLRP on the basis of clinical
presentation (e.g., early onset and severity of disease)
(total of 55; class C).
Informed consent was obtained from patients and
healthy subjects after the nature of the procedures had
been fully explained. The research protocols were ap-
proved by the institutional review boards of the Uni-
versity of Michigan and all other collaborating institu-
tions and were in accordance with the Declaration of
Helsinki. Referring clinicians provided control DNA
samples from unaffected individuals with no family his-
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Table 1
Mutations in the RP2 Gene in Affected Hemizygotes with
XLRP
Mutationa Protein Changeb Exon Patient(s)
Deletion:
409-411del Ile37del 2 1694
350-351del Phe117fsTer155 2 471
Insertion:
515insG Ser172fsTer173 2 790
670insC Arg225fsTer234 2 1358
Splice site:
IVS13ArG Int1 115
Nonsense:
82CrG Tyr27Ter 1 1645
Missense:
200GrA Cys67Tyr 2 1699
353GrA Arg118His 2 1324 and 1737
565TrC Leu188Pro 2 1063
a Nucleotide positions are based on GenBank sequence (ac-
cession number NM_006915), with the first nucleotide of the
initiation codon ATG designated as base 1.
b Frameshift mutations are designated according to the fol-
lowing example: Phe117fsTer155 refers to a frameshift muta-
tion, in which Phe117 is the first amino acid altered, with ter-
mination of the open reading frame at residue 155.
tory of retinal disease. DNA was extracted from lym-
phocytes by use of standard procedures.
Mutation Analysis
Of the 234 families, 49 were previously screened for
RPGR (Buraczynska et al. 1997) and 63 for RP2 (Mears
et al. 1999). In the present study, we performed the mu-
tation screening of 185 probands for RPGR and 171 for
RP2 by directly sequencing theRPGR (includingORF15)
and RP2 genes, including their 5′ upstream regions. The
newmutations identified in this studywere combinedwith
the previously reported mutations for a comprehensive
cohort analysis. Eighteen primer sets forRPGR-promoter
exon 19 (Meindl et al. 1996), two primer sets forORF15
(Vervoort et al. 2000), and five primer sets for RP2 exons
(Schwahn et al. 1998) were synthesized at the Biomedical
Research Core Facility of the University ofMichigan and/
or by Invitrogen. The primer sets amplify each exon and
at least 25 bp of intronic sequence on either end. The
primer pairs for the 5′ upstream regions of RP2 and
RPGR were designed from the genomic sequences (Gen-
Bank accession numbers NT_011572 [RP2] and
AJ318463 [RPGR]) and are as follows: RP2-1F: 5′-TTG-
CTCGAGAGGCTTTGATT-3′; RP2-1R: 5′-GACTTCA-
GCTATCCGCGTTC-3′; RPGR-1F: 5′-GACTAGCTGC-
CCACATGCTTAAAC-3′; and RPGR-1R: 5′-GGATGG-
GGGAGAACGGGAAA-3′. Amplified products were pu-
rified either with Qiaquick columns (Qiagen) or with the
MultiScreen PCR system (Millipore). Products were se-
quenced by the University of Michigan DNA sequencing
core using reagents (BigDye version 1) and automated
sequencers (models 373, 377, and 3700) from Applied
Biosystems, according to the manufacturer’s protocols.
Sequence variations were confirmed using the ThermoSe-
quenase Cycle Sequencing Kit (AmershamPharmacia Bio-
tech). Sequences were aligned using Sequencher (Gene
Codes). Mutations were confirmed by analyzing available
family members. Sequence variations were deemed pu-
tative mutations if they were predicted to result in a trun-
cated protein, had not been previously reported as poly-
morphisms (Sharon et al. 2000; Vervoort et al. 2000),
or were not identified in a screen of 200 normal
chromosomes.
Results
Mutations and Sequence Variations in RP2
Direct sequencing of the PCR products spanning all
exons, exon-intron boundaries, and the 5′ upstream re-
gion of the RP2 gene revealed nine different mutations
in 10 of the 171 patients examined; of these, eight are
novel mutations (table 1 and fig. 1). These mutations
cosegregated with the disease in all available family
members.
Frameshift, nonsense, and splice-site mutations.—Four
frameshift mutations—small deletions or insertions—
were detected in exon 2 in four patients. Tyr27Ter, a
novel nonsense mutation, was found in one of the pro-
bands. IVS13ArG is a novel mutation and is predicted
to affect the acceptor site of intron 1. The same nucle-
otide was altered in a previously reported mutation as
a transversion (Sharon et al. 2000). Six of the seven
mutations in this group are predicted to generate a trun-
cated protein before or within the cofactor C homology
domain. The seventh mutation has been previously re-
ported and would result in the deletion of Ile137, a con-
served residue in the cofactor C homology domain.
Missense mutations.—Three missense mutations, two
of which are novel, were found in four of the probands.
These missense mutations were not observed in 1200
chromosomes from healthy individuals. The Cys67Tyr
mutation is predicted to change a potential disulfide
bond–forming conserved residue to a larger neutral amino
acid in the cofactor C homology domain. Arg118His and
Leu188Pro are mutations in residues that are conserved
between RP2 and the human cofactor C protein.
Sequence variations and polymorphisms.—One poly-
morphic change, 844CrT, was observed in two patients
in the mutation screen (table 2). This sequence variation
has been reported elsewhere (Sharon et al. 2000) and
was detected in both affected and unaffected individuals.
Mutations and Sequence Variations in RPGR
Analysis of RPGR exons 1–19 revealed eighteen dif-
ferent mutations in 19 of the 185 independent XLRP
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Figure 1 Location of all known mutations in RP2. The right
side designates mutations identified in this screen; all previously re-
ported mutations are shown on the left.
Table 2
Sequence Variations and Polymorphisms in the RP2 and
RPGR Genes
SEQUENCE CHANGE LOCATION
% IN POPULATION
Patient Unaffecteda
RP2:
844CrTb Exon 3 1.6 ND
RPGR:
8CrA Promoter 2.2 2.5
IVS1-15ArGb Intron 1 3.8 ND
212CrT Exon 3 .5 ND
1146TrA Exon 10 0 1.4
1223GrTb Exon 10 13.0 4.9
IVS1016ArGb Intron 10 1.1 ND
1333GrAb Exon 11 2.2 9.2
1350ArGb Exon 11 1.1 6.3
1354ArG Exon 11 0 .5
1426ArG Exon 11 1.6 1.9
IVS12101TrAb Intron 12 2.7 ND
IVS12100 1-bp insb Intron 12 2.2 ND
IVS1297TrCb Intron 12 1.6 ND
IVS1293 2-bp insb Intron 12 13.5 ND
IVS1311ArGb Intron 13 1.6 ND
1635-1637del Exon 14 1.1 ND
1657CrT Exon 14 1.1 1.4
1746GrA Exon 14 2.7 7.2
IVS16137TrA Intron 16 2.7 ND
IVS1746CrTb Intron 17 2.7 ND
IVS1811TrCb Intron 18 23.2 ND
RPGR-ORF15:c
863ins, 21 bp .8 ND
915-917del .8 ND
965-967del 7.4 ND
1052-1072dup 1.7 ND
1221-1235del .8 ND
1299-1310del 9.1 ND
1309-1320del .8 ND
a ND p not determined.
b Previously identified polymorphisms (Sharon et al. 2000).
c Previously identified polymorphisms (Vervoort et al. 2000).
patients that were examined (table 3 and fig. 2). All
mutations cosegregated with the disease in available
family members.
Frameshift, nonsense, and splice-site mutations.—Of
the 18 mutations, 11 (five frameshift, two splice-site, and
four nonsense mutations) are predicted to result in a
truncated protein. Two of the frameshift mutations have
been reported previously, whereas four are novel. Nine
of the mutations are predicted to truncate a part of the
RLD. Two other mutations are predicted to truncate the
protein after exon 11 or 14, thereby leaving the RLD
intact but deleting the entire ORF15 region. An addi-
tional previously reported mutation is predicted to delete
the Leu258 codon.
Two mutations, one of which is novel, were detected
in conserved residues at intron/exon splice sites. One of
these is in the donor site of intron 4, and the other is in
the donor site of intron 10. Four nonsense mutations,
three of which are novel, were identified in four inde-
pendent patients. Each of these is predicted to result in
a truncation of the RPGR protein prior to exon 12 and
delete a part of RLD.
Missense mutations.—In this mutation screen, we iden-
tified six missense mutations that were not detected in at
least 200 normal chromosomes. One of these,Arg137Gly,
has been previously reported, whereas the remaining five
are novel. Gly173Arg affects a residue conserved between
RPGR and RCC1, whereas Cys250Tyr, Gly266Arg,
Glu285Gly, and Gly436Asp mutations alter residues in
the RLD, supporting the importance of this domain in
RPGR function.
Sequence variations and polymorphisms.—Twenty-
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Table 3
Mutations in the RPGR Gene in Affected Hemizygotes with
XLRP
Mutationa Protein Changeb Exon Patient(s)
Deletion:
541-542del Phe162fsTer165 6 913
688-698del Glu210fsTer214 7 310
830-832del Leu258del 7 652
1431-1432del Cys458fsTer461 11 774
1744-1745del His562fsTer581 14 688
Insertion:
1335ins 2bp Ile407fsTer452 10 770 and 413
Splice site:
IVS41 GrC Int4 163
IVS102 TrC Int10 1689
Nonsense:
474GrT Glu139Ter 5 333
551GrA Trp164Ter 6 102
1293CrT Arg412Ter 10 725
1404CrT Arg449Ter 11 902
Missense:
438ArG Arg127Gly 5 1745
576GrC Gly173Arg 6 1734
808GrA Cys250Tyr 7 555
859GrA Gly266Arg 8 1708
924ArG Glu285Gly 8 1661
1366ArG Gly436Asp 11 767
a Nucleotide positions and nomenclature are based on the
work of Meindl et al. (1996) and Buraczynska et al. (1997).
b Frameshift mutations are designated according to the fol-
lowing example: Phe162fsTer165 refers to a frameshift muta-
tion, in which Phe162 is the first amino acid altered, with ter-
mination of the open reading frame at residue 165.
Figure 2 Location of all known mutations in RPGR. The right
side designates mutations identified in this screen; all previously re-
ported mutations are shown on the left.
one sequence variations, nine of which are novel, were
identified in this study. Table 2 lists the variations and
their frequency in our normal and patient cohort.
Mutations in RPGR-ORF15
The RPGR exon ORF15 was analyzed for mutations
by direct sequencing of PCR products with multiple in-
ternal primers. Our analysis revealed 21 different mu-
tations in 41 of the 195 patients examined and includes
17 frameshift and four nonsense mutations (table 4 and
fig. 3). All of the frameshift mutations alter the predicted
protein sequence for at least 19 amino acids prior to
termination. One of these is predicted to truncate the
RPGR protein after 86 altered amino acids.
Discussion
This is the first comprehensive report ofmutation screen-
ing in a large cohort affected with XLRP in which the
RP2 and RPGR (including ORF15) genes and their 5′
upstream regions were directly sequenced in affected
male probands. Our results establish a molecular defi-
nition of XLRP in a North American population and
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Table 4
Mutations in RPGR-ORF15 in Affected
Hemizygotes with XLRP
Mutationa Protein Changeb
No. of
Patients
Affected
Deletion:
432del Glu146fsTer232 1
481-2del Arg162fsTer184 9
481-4del Arg162fsTer231 1
500-3del Lys168fsTer231 1
504-7del Gly170fsTer231 1
571-2del Arg192fsTer250 1
632del Glu212fsTer231 1
651-2del Glu219fsTer250 6
653-4del Glu219fsTer250 1
659-670del Glu223fsTer250 1
673-4del Glu226fsTer250 2
690-3del Glu232fsTer235 3
1183-4del Glu397fsTer495 1
1243-4del Glu417fsTer495 1
1338-9del Glu448fsTer495 1
Insertion:
186ins, 5bp Ala63fsTer113 1
353-461dup 1
Nonsense:
370GrT Glu125Ter 1
394GrT Glu133Ter 1
424GrA Glu143Ter 3
508GrT Glu171Ter 3
a Nucleotide positions and nomenclature
are based on the work of Vervoort et al. (2000).
b Frameshift mutations are designated ac-
cording to the following example:
Glu146fsTer232 refers to a frameshift muta-
tion, in which Glu146 is the first amino acid
altered, with termination of the open reading
frame at residue 232.
Figure 3 Location of all known mutations in RPGR-ORF15.
The right side designates mutations identified in this screen; all mu-
tations reported by Vervoort et al. (2000) are shown on the left.
provide essential information for the development of ge-
notype-phenotype correlations for this heterogeneous
disease. Together with our previous studies (Buraczynska
et al. 1997; Fujita et al. 1997; Mears et al. 1999), we
have performed a systematic analysis of 234 independent
probands with a confirmed diagnosis of RP and probable
X-linked recessive inheritance and have identified po-
tential disease-causing mutations in approximately half
of the families. Several of the reported mutations in the
two genes are novel (see figs. 1, 2, and 3). Almost all of
the newly discovered mutations are localized in the co-
factor C homology domain of RP2 or in the RLD or
exon ORF15 of RPGR, illustrating their functional
significance.
In our studies, the observedmutation frequency inRP2
and original RPGR exons 1–19 is 6% and 15%, re-
spectively, and thus is in concordance with previous mu-
tation screens (Buraczynska et al. 1997; Fujita et al. 1997;
Hardcastle et al. 1999; Mears et al. 1999; Sharon et al.
2000). Surprisingly, however, we could identify RPGR-
ORF15 mutations in only 22% of our cohort, which is
considerably lower than the published report of 60%
(Vervoort et al. 2000). Interestingly, no causative muta-
tions were detected in the 5′ upstream regions of the two
genes. Although all the probands in our study cohort
carry a diagnosis of typical RP, the nature of several
family structures, variations in disease manifestation in
carrier females, and clinical phenotypes might support
an autosomal pattern of inheritance in some of the fam-
ilies. Consequently we divided our cohort into categories
defined by the evidence supporting X-linked inheritance
(table 5). In category A, where the evidence for X-linked
inheritance was the strongest, causative mutations were
identified in 62%of patients (7% inRP2, 25% inRPGR,
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Table 5
Distribution of Mutations in the North American XLRP Cohort
CATEGORY
NO. OF
FAMILIES
NO. (%) OF MUTATIONS FOUND IN
RP2 RPGR ORF15 Total
A 91 6 (7) 23 (25) 27 (30) 56 (62)
B 88 6 (7) 6 (7) 16 (18) 26 (32)
C 55 3 (5) 5 (9) 8 (15) 16 (29)
Total 234 15 (6) 34 (15) 51 (22) 100 (43)
Clinician-referred 160 12 (8) 26 (16) 42 (26) 80 (50)
RPRC-referred 74 3 (4) 8 (11) 9 (12) 20 (27)
and 30% in RPGR-ORF15). The disease locus in several
category A families has been tightly linked to RP3; how-
ever, this screen failed to identify causative RPGR mu-
tations (Fujita et al. 1997; D. K. Breuer, B. M. Yashar,
and A. Swaroop, unpublished data). In class B, only 32%
of the patients had mutations (7% inRP2, 7% inRPGR,
and 18% in RPGR-ORF15). This frequency is similar
to class C (single affected males) where 29% of patients
have mutations (7% in RP2, 7% in RPGR, and 18% in
RPGR-ORF15). The latter finding is particularly signif-
icant since it suggests that mutations in RP2 and RPGR
may account for disease in a considerable proportion of
simplex cases that account for almost 50% of RP. We
estimate that RPGR mutations would therefore be re-
sponsible for 15%–20% of all cases of RP, higher than
any other single genetic locus.
Several possibilities can be put forward to explain
why no mutation has been detected in almost 40% of
even class A XLRP patients.
1. We examined 1300 bp of the 5′ upstream regions
of the RP2 and RPGR genes. Sequence changes in fur-
ther upstream promoter or enhancer elements may affect
gene expression.
2. Disease-associated mutations present within in-
tronic sequences may alter the splicing pattern. Muta-
tions at the branch-point are known to result in defective
splicing in the FBN2 gene (Maslen et al. 1997).
3. RPGR is a large and highly complex gene in which
new exons continue to be identified (Kirschner et al.
1999; Vervoort et al. 2000). We had also screened an-
other reported exon 15a (Kirschner et al. 1999) in 43
families, but we did not detect any sequence variation.
An additional exon, ORF14, was identified in the same
analysis that yieldedORF15 (Vervoort et al. 2000); how-
ever, it was not screened in this study, since a previous
study found no evidence for disease mutations. Another
mutational hotspot in an as-yet-unidentifiedRPGR exon
remains a possibility.
4. Another gene tightly linked to the region offers an
alternative scenario. RP6, a locus for which the gene has
yet to be cloned, is located !5 cM from RP3 (Breuer et
al. 2001) and is a valid candidate for future investigations.
The findings in this study may reflect a population dif-
ference, with the disease in our North American cohort
attributable to a mutational hotspot in another exon of
RPGR or another gene.
Since the vast majority of RPGR or RP2 mutations
are predicted to result in a truncated protein product,
our study strongly argues that the XLRP disease state
is caused by the loss of function of RP2 or RPGR. This
finding has significant implications for genetic diagnosis
and gene-based therapy. The utility of a genetic test is
dependent on specificity (the frequency with which the
test yields a negative result when the disease is absent)
and sensitivity (the frequency with which the test yields
a positive result when the disease is present) (Gelehrter
et al. 1998). Because of extensive alternative splicing
and a lack of identifiable RPGR mutations even in ge-
netically-linked RP3 families, molecular testing by di-
rect sequencing will have low specificity; nevertheless,
it might be possible to greatly enhance the informa-
tiveness of testing by analyzing protein products in lym-
phocytes of at-risk males and carrier females. Protein-
truncation tests have been applied successfully in studies
of the BRCA1 gene for breast cancer, the APC gene for
colon cancer, and the CHM gene mutated in choroid-
eremia (MacDonald et al. 1998; Balhausen 2000;
Moore et al. 2000). With suitable RPGR- or RP2-spe-
cific antibodies, it may also be possible to identify mu-
tations in the remainder of our cohort, if such changes
alter the protein structure. We also suggest that a gene-
based therapy that delivers a wild-type RPGR or RP2
gene to the retina might be sufficient to correct the gene
defect. Early applications of gene therapy to the treat-
ment of retinopathies have provided strong proof of
principle (Bennett and Maguire 2000; Hauswirth and
Beaufrere 2000; Bessant et al. 2001). A successful move-
ment of this approach from research to clinical appli-
cation will also depend on understanding the kinetics
of the retinal degenerative process and administering
the therapy early in the disease progression, while there
are still viable photoreceptors. XLRP, like most genetic
diseases, displays inter- and intrafamilial variability in
the average age at onset of disease (Bird 1975; Fishman
et al. 1988). Early molecular diagnosis of at-risk males
should allow identification of the best patient candidates
for therapeutic intervention. In summary, our study of-
fers an important molecular definition of theXLRP pop-
ulation in North America and lays the groundwork for
the future development of diagnostic testing and gene-
based therapies for XLRP.
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